Younossi Zobair M, Stepanova Maria, Kim Yestle, Dodge Stephen, Labriola Dominic, Taub Rebecca, Nader Fatema
The Global MASH Council, Washington, District of Columbia.
Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia.
Gastro Hep Adv. 2025 Feb 7;4(6):100642. doi: 10.1016/j.gastha.2025.100642. eCollection 2025.
The EuroQol-5D (EQ-5D) is a commonly used measure of health utilities to calculate quality-adjusted life years. For the clinical trials that use Chronic Liver Disease Questionnaire-nonalcoholic fatty liver disease (CLDQ-NAFLD) or Short Form-36 (SF-36), ability to convert the health-related quality of life scores (CLDQ-NAFLD or SF-36) to EQ-5D scores provides a valuable method to estimate health utility.
Baseline data of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) patients were used in this study. We used 2 cross-walk algorithms to estimate EQ-5D scores. The first algorithm used 6 domains of CLDQ-NAFLD in a fractional logistic model to yield EQ-5D estimates. The other algorithm included calculation of SF-6D utility scores from SF-36 items, which were fed into a regression model that estimated EQ-5D scores from SF-6D scores.
There were 883 MASH patients with CLDQ-NAFLD and SF-36 data: 25% ≥65 years, 44% male, 80% obese (body mass index >30), 67% type 2 diabetes, 62% F3 fibrosis, and 38% F1B/F2 fibrosis. The mean estimated EQ-5D scores were 0.851 (standard deviation = 0.146) according to CLDQ-NAFLD-based algorithm and 0.853 (standard deviation = 0.097) according to the SF-36-based algorithm. The correlations between the 2 estimated EQ-5D scores were up to +0.74. Similar to the total sample, the differences between the mean EQ-5D estimates using either calculation method did not exceed 0.012 in all studied subgroups (by age, sex, obesity, type 2 diabetes, and fibrosis stage).
Both cross-walk algorithms for the calculation of the EQ-5D utility scores in MASH patients were estimable with CLDQ-NAFLD or SF-36 instruments. A high positive correlation was seen between the total score and subgroup estimates using either method.
欧洲五维健康量表（EQ-5D）是一种常用的健康效用测量工具，用于计算质量调整生命年。对于使用慢性肝病问卷-非酒精性脂肪性肝病（CLDQ-NAFLD）或简短健康调查问卷（SF-36）的临床试验而言，将健康相关生活质量评分（CLDQ-NAFLD或SF-36）转换为EQ-5D评分的能力提供了一种评估健康效用的重要方法。
本研究使用了非肝硬化代谢功能障碍相关脂肪性肝炎（MASH）患者的基线数据。我们采用两种交叉转换算法来估计EQ-5D评分。第一种算法在分数逻辑模型中使用CLDQ-NAFLD的6个维度来得出EQ-5D估计值。另一种算法包括从SF-36项目计算SF-6D效用评分，然后将其输入一个根据SF-6D评分估计EQ-5D评分的回归模型。
共有883例有CLDQ-NAFLD和SF-36数据的MASH患者：25%年龄≥65岁，44%为男性，80%肥胖（体重指数>30），67%患有2型糖尿病，62%为F3纤维化，38%为F1B/F2纤维化。根据基于CLDQ-NAFLD的算法，平均估计EQ-5D评分为0.851（标准差=0.146）；根据基于SF-36的算法，平均估计EQ-5D评分为0.853（标准差=0.097）。两种估计的EQ-5D评分之间的相关性高达+0.74。与总样本相似，在所有研究亚组（按年龄、性别、肥胖、2型糖尿病和纤维化阶段划分）中，使用任何一种计算方法得出的平均EQ-5D估计值之间的差异均不超过0.012。
使用CLDQ-NAFLD或SF-36工具，两种用于计算MASH患者EQ-5D效用评分的交叉转换算法都是可估计的。使用任何一种方法得出的总分与亚组估计值之间均呈现高度正相关。
